NOTESKARTS

Making Notes Simple

B.Pharm 8th Semester

BP803ET

PHARMA MARKETING MANAGEMENT

(Theory) — 45 Hours

UNIT — V PRICING & EMERGING MARKETING CONCEPTS

As per PCI / AKTU Syllabus

www.noteskarts.com

UNIT — V PRICING & EMERGING MARKETING CONCEPTS (07 Hours)

UNIT V SYLLABUS — AT A GLANCE (07 Hours)

PART A — PRICING

1. Meaning & Importance of Price
2. Objectives of Pricing
3. Determinants of Price
4. Pricing Methods
5. Pricing Strategies
6. Price Management Issues in Pharma
7. DPCO — Drug Price Control Order
8. NPPA — National Pharmaceutical Pricing Authority

PART B — EMERGING CONCEPTS

9. Vertical Marketing Systems (VMS)
10. Horizontal Marketing Systems (HMS)
11. Rural Marketing
12. Consumerism
13. Industrial Marketing
14. Global Marketing

PART A — PRICING IN PHARMACEUTICAL MARKETING

PRICE — Meaning, Definition & Importance

📌 **Definition:** Price is the amount of money charged for a product or service, or the sum of the values that consumers exchange for the benefits of having or using the product or service. In pharmaceutical marketing, price is the only element of the marketing mix (4Ps) that generates revenue — all other elements (Product, Place, Promotion) represent costs.

Importance of Pricing in the Pharmaceutical Industry

Dimension	Why Pricing Matters	Pharma Context
Revenue Generation	Price × Volume = Revenue — sole income source for the company	Correct pricing of a blockbuster drug funds R&D for next-generation molecules
Market Access	Price determines who can afford the medicine	High pricing of life-saving cancer drugs limits patient access in low-income countries
Competitive Positioning	Price signals quality and brand position	Premium pricing of an innovator vs. generic signals 'quality assurance'

Dimension	Why Pricing Matters	Pharma Context
Regulatory Compliance	Pharma prices are legally controlled in India under DPCO	Failure to comply with NPPA ceiling prices invites penalties
R&D Recovery	New drug development costs USD 1–2 billion; pricing must recover investment	High launch prices for NCEs (New Chemical Entities) reflect sunk R&D costs
Social Responsibility	Medicines are not ordinary products — pricing affects public health	Compulsory licensing, DPCO, Jan Aushadhi — government tools to check pharma pricing
Profit & Sustainability	Adequate margins fund operations, MR salaries, distribution costs	Thin margins on essential generic drugs challenge company viability

Point: Price is unique among the 4Ps — it is the only element that generates revenue. It is also the most flexible element, capable of being changed faster than product, place, or promotion decisions.

OBJECTIVES OF PHARMACEUTICAL PRICING

A pharmaceutical company must define clear pricing objectives before setting any specific price. These objectives reflect the company's broader marketing and corporate strategy:

- **1. Survival:** In highly competitive markets with intense generic competition or post-patent expiry, companies may price just above variable cost to maintain cash flow and survive. Short-term objective — not sustainable long-term. Example: Price reductions post-DPCO notification.
- **2. Maximum Current Profit:** Setting price to maximise short-term profit — common for recently launched innovator drugs still under patent protection. Requires accurate demand and cost estimation.
- **3. Maximum Market Share (Market Penetration):** Setting a lower introductory price to gain rapid market share and discourage competitors. Example: Aggressive pricing by Indian generic companies entering new therapeutic segments.

- **4. Market Skimming:** Setting a high initial price for innovative products to 'skim' the premium segment, then gradually reducing price as competition increases. Common for NCEs, biologics, and specialty drugs at launch.
- **5. Product Quality Leadership:** Pricing the product higher to signal premium quality — supports brand equity of MNC pharma companies. Example: Branded antibiotics priced 5–10× over generic equivalents.
- **6. Social Pricing / Affordability:** Setting price with access and affordability in mind — especially for essential medicines, anti-TB, anti-malarial drugs. Government-mandated through DPCO and Jan Aushadhi scheme.
- **7. Competitive Parity Pricing:** Setting price in line with competitors in the same therapeutic class — avoids price war while maintaining market position.
- **8. Return on Investment (ROI) Pricing:** Setting price to achieve a specific percentage return on the investment made in R&D, manufacturing, and marketing.

DETERMINANTS OF PHARMACEUTICAL PRICE

Price determination in the pharmaceutical industry is influenced by a complex interplay of internal and external factors:

Internal Determinants (Company-Controlled Factors)

- **Cost of Production:** Manufacturing cost (API + excipients + labour + overheads) forms the price floor — the minimum acceptable price. Cost-Plus pricing builds profit margin over this.
- **Research & Development (R&D) Costs:** NCE development costs USD 1–2 billion over 10–12 years — must be recovered through product pricing during the patent-exclusivity period.
- **Marketing & Promotional Costs:** MR field force expenses, CME programs, sampling, journal ads — all add to the cost base that price must cover.
- **Company Pricing Objectives:** Profit maximisation, market share, survival — each leads to different price points (as described in Section 2).
- **Product Differentiation:** A uniquely differentiated drug (better efficacy, fewer side effects, novel delivery system) commands premium pricing.
- **Stage in Product Life Cycle:** Introduction stage — skimming price; Growth — maintain premium; Maturity — reduce to defend share; Decline — minimal, harvest pricing.

External Determinants (Market-Controlled Factors)

External Factor	Influence on Pharma Pricing	Example
Demand & Price Elasticity	Inelastic demand for essential life-saving drugs (insulin, cancer drugs) allows premium pricing; elastic demand for OTC products requires competitive pricing	Insulin demand remains constant despite price — inelastic; OTC vitamin pricing elastic
Competition	More competitors in a therapeutic class drives price down; patent-protected innovator commands premium	30+ brands of Atorvastatin at different price points; vs. new biologic with no competitor
Regulatory Controls (DPCO)	Government mandates ceiling prices for scheduled drugs under DPCO — company cannot price above this	Atorvastatin ceiling price set by NPPA — companies must comply
Channel Margins	Distributor (7–10%), retailer (18–20%) margins must be built into MRP — affects final consumer price	MRP includes all channel margins + company profit + taxes
Payer Landscape	Insurance companies, government procurement (GEMCORP, TNMSC) negotiate bulk discount prices	Government tender price may be 80% lower than open market MRP
Import/Export Costs	API import duties, exchange rate fluctuations impact production cost and pricing	Rupee depreciation increases API import cost → upward pressure on prices
Patient Income Levels	Per capita income determines affordability; tiered pricing for income groups	Premium brand for urban hospitals + affordable branded generic for Tier 2/3 cities
Patent Status	Patent-protected = monopoly pricing; Post-patent = generic competition crushes price	Imatinib (Gleevec): ₹1.2 lakh/month under patent → ₹8,000/month post-patent

PRICING METHODS IN PHARMACEUTICAL MARKETING

Pricing methods are the systematic approaches used to calculate the specific price for a pharmaceutical product:

Cost-Based Pricing Methods

- **A. Cost-Plus (Mark-Up) Pricing:** The most commonly used method. Price = Total Cost per Unit + Profit Mark-up Percentage.

Formula: MRP = Manufacturing Cost + Channel Margins + Profit Margin + GST Example: API cost ₹5 + Mfg cost ₹3 + Overheads ₹2 = Cost ₹10 Mark-up 200% → Selling price ₹30 + GST + Channel margins → MRP ₹50	**Advantages:** • Simple and straightforward to calculate • Ensures all costs are covered • Widely accepted by regulators **Disadvantages:** • Ignores demand and competition • May be too high or too low for market

- **B. Target Return Pricing:** Sets price to achieve a specific ROI on investment. Price = Unit Cost + (Desired Return × Invested Capital) / Expected Unit Sales. Used by innovator companies to recover NCE development investment.
- **C. Break-Even Pricing:** Price is set at the level where Total Revenue = Total Costs. Below break-even: loss; above: profit. Useful for calculating the minimum viable price for a new generic launch.

Competition-Based Pricing Methods

- **Going-Rate Pricing:** Setting price at the level of the dominant competitor or industry average. Common in crowded generic segments. Example: Pricing a new Metformin brand at the same level as market leader.
- **Competitive Bidding / Tender Pricing:** Price determined through competitive bid process for government procurement, hospital tenders. Price must be competitive enough to win but above cost. Example: TNMSC (Tamil Nadu) drug tender — companies bid lowest price to win contract.
- **Perceived Value Pricing:** Price based on buyer's perceived value of the product rather than seller's cost. Premium brands justify higher prices through superior clinical data, brand reputation, and physician trust. Example: Branded

Atorvastatin at ₹150/strip vs. generic at ₹15/strip — physician's trust in brand justifies the premium.

Demand-Based Pricing Methods

- **Value-Based Pricing:** Price reflects the total therapeutic and economic value delivered to patients and the healthcare system. Example: A drug that prevents hospitalisation costing ₹50,000/year is priced at ₹20,000/year — offering net value savings.
- **Differential / Tiered Pricing:** Different prices for different market segments based on their ability to pay. Example: Same drug priced at ₹10/tablet in government supply, ₹50/tablet for insurance-covered patients, and ₹100/tablet for private premium market.
- **Psychological Pricing:** Using price points that create a perception of value — e.g., pricing at ₹99 instead of ₹100, or ₹199 instead of ₹200.

PRICING STRATEGIES IN PHARMACEUTICAL MARKETING

Pricing Strategy	Description	When Used	Pharma Example
Market Skimming (Price Skimming)	Set high initial price to extract maximum value from premium segment before gradually reducing	Patent-protected NCEs, biologics, specialty drugs at launch	New oncology drug launched at ₹2 lakh/month; price reduced as biosimilars enter
Market Penetration Pricing	Set low price at launch to gain rapid market share and deter competition	Generic drug market entry; OTC product launch in competitive category	Indian generic company pricing Cefixime 30% below market leader to capture prescribers quickly
Competitive Pricing	Price at par with or slightly below key competitor	Maturity stage; crowded therapeutic category	One of 20 Atorvastatin brands pricing at ₹3/tablet vs. competitor's ₹3.20
Premium Pricing	Price significantly above competition based on brand equity and perceived superiority	MNC innovator brands; trusted established generics	GlaxoSmithKline Augmentin priced 5× above generic

Pricing Strategy	Description	When Used	Pharma Example
			Amoxicillin-Clavulanate brands
Economy Pricing	Lowest possible price by minimising costs; targeting price-sensitive mass market	Unbranded generics; Jan Aushadhi stores; tender market	Jan Aushadhi Metformin at ₹2/tablet vs. branded at ₹8–₹12/tablet
Psychological Pricing	Use of price points to create value perception	OTC and nutraceutical products	Vitamin C supplement at ₹199 rather than ₹200
Bundle/Value Pack Pricing	Offering combination products or multi-pack at discounted price	Chronic therapy where compliance is critical	3-month supply pack of antihypertensive at 10% discount vs. monthly pack
Geographic Pricing	Different prices for different geographies based on market conditions	Urban vs rural; domestic vs export markets	Export price to Africa may be 60% lower than Indian MRP for same antibiotic

ISSUES IN PRICE MANAGEMENT IN PHARMACEUTICAL INDUSTRY

Major Price Management Challenges

- **1. Price Regulation (DPCO Compliance):** Government-imposed ceiling prices restrict pricing freedom for scheduled drugs. Companies must monitor NPPA notifications and revise prices within the stipulated timeframe. Non-compliance attracts financial penalties.
- **2. Patent Cliff & Generic Price Erosion:** When a blockbuster drug loses patent protection, generic entry causes 70–90% price erosion within 12–18 months. Companies must plan lifecycle management well before patent expiry to maintain revenue.
- **3. Price Parallelism / Reference Pricing:** In global markets, price in one country affects price negotiations in another (international reference pricing). Indian prices — already among the world's lowest — are referenced by other developing countries.

- **4. Counterfeit & Spurious Drug Market:** Low-priced spurious drugs undercut legitimate products in price-sensitive markets, eroding sales while endangering patient safety.
- **5. Channel Margin Management:** Balancing margins across C&F (1–2%), stockist (7–10%), and retailer (18–20%) while maintaining competitive MRP requires continuous management. Trade disputes over margin levels can disrupt distribution.
- **6. GST Impact on Drug Pricing:** Introduction of GST created pricing complexity — different GST rates (0%, 5%, 12%, 18%) for different drug categories. Exempted essential medicines vs. taxed OTC products create pricing discrepancies.
- **7. Differential Pricing (Urban vs. Rural):** Price sensitivity varies widely between urban and rural markets. Uniform MRP (mandated in India) makes rural market pricing challenging — companies address this through pack size variation (smaller, more affordable pack sizes for rural markets).
- **8. Price Increase Restrictions:** Non-scheduled drugs can increase MRP by only 10% per annum (as per Trade Margins Rationalisation Order). Any increase must be justified and notified to NPPA.
- **9. E-Pharmacy Discounting:** Online pharmacies (1mg, PharmEasy) offer 15–20% discounts on MRP — creating tension with retail chemists who sell at MRP. Companies face pressure to rationalise MRP or allow differential pricing for digital channels.
- **10. International Price Differential:** Same drug priced dramatically differently in different countries — e.g., an HIV drug at ₹500/month in India vs. USD 5,000/month in USA — creates ethical and regulatory debates about global access.

⚠ **Important:** Price management in pharma is not purely a commercial decision — it has profound public health implications. The balance between industry sustainability (funding R&D) and patient affordability is the central tension in pharmaceutical pricing policy globally.

DRUG PRICE CONTROL ORDER (DPCO)

📌 **Definition:** The Drug Price Control Order (DPCO) is a statutory order issued by the Government of India under the Essential Commodities Act, 1955

that empowers the government to control the prices of essential pharmaceutical products (Scheduled Drugs) in the country. The current operative order is DPCO 2013.

Historical Evolution of DPCO

Order	Year	Key Features
DPCO 1970	1970	First price control order; 347 drugs under control; extensive regulation of the industry
DPCO 1979	1979	347 formulations covered; manufacturer required to seek prior government approval for pricing
DPCO 1987	1987	Reduced controlled drugs to 142; retained cost-based pricing formula
DPCO 1995	1995	Further reduced to 74 bulk drugs; introduced market-based pricing for non-scheduled drugs
DPCO 2013	2013 (Current)	Market-based ceiling price formula; 348 formulations under National List of Essential Medicines (NLEM 2011); NPPA empowered to fix prices based on simple average of all brands with >1% market share

Provisions of DPCO 2013

- Coverage: All formulations listed in the National List of Essential Medicines (NLEM) are 'Scheduled Formulations' under price control.
- Price Fixation Formula: Ceiling Price = (Average price of all brands with market share ≥1%) × (1 + Maximum Allowable Post-Manufacturing Expense/MAPE = 16%).
- Non-Scheduled Formulations: Manufacturers can fix their own prices but annual increase is capped at 10%.
- Ceiling Price Notification: NPPA publishes ceiling prices in the official gazette; companies must comply within the specified period.
- Price Revision: Prices can be revised annually based on WPI (Wholesale Price Index) — scheduled drug prices are adjusted by WPI percentage change.
- Overpricing Penalty: Companies charging above the notified ceiling price are liable to pay 15% interest on the excess amount recovered, which is deposited to the government.
- Exemptions: Patented drugs, orphan drugs, drugs priced below ₹2 per unit are exempt from price control under DPCO.

Scheduled vs. Non-Scheduled Drug Pricing

Aspect	Scheduled Drugs (NLEM)	Non-Scheduled Drugs
Price Control	Subject to DPCO ceiling price set by NPPA	No ceiling price — company sets own MRP
Annual Increase	Linked to WPI (Wholesale Price Index) change	Maximum 10% per year
Examples	Paracetamol, Metformin, Atorvastatin, Amoxicillin, Insulin	OTC vitamins, branded specialty drugs, cosmetics
Monitoring	Strictly monitored by NPPA and state drug controllers	Monitored by NPPA for reasonable pricing
Current Number	~870 formulations in NLEM 2022 (revised NLEM)	All other marketed formulations

Point: NLEM 2022 (National List of Essential Medicines 2022) contains 384 medicines across 27 therapeutic categories — the updated list from NLEM 2011. These are the drugs considered essential for addressing India's primary healthcare needs.

Impact of DPCO on the Pharmaceutical Industry

Impact Area	Effect of DPCO
Revenue Impact	Significant revenue loss for companies when brands brought under price control — can be 20–50% revenue reduction
R&D Incentive	Low drug prices reduce profit margins available to fund R&D; concerns about innovation sustainability
Market Access	Improved patient access to affordable essential medicines — DPCO's primary social objective
Generic Promotion	Price-controlled branded drugs compete more fairly with generics; encourages rational prescribing
Company Strategy	Companies shift focus to non-scheduled drugs, specialty drugs, and export markets to avoid price control impact
Trade Conflict	Chemist associations have boycotted certain company products when DPCO reduces retail margin below acceptable levels

★ **Exam Tip:** DPCO 2013 is a very high-frequency exam topic. Key facts: NLEM-based coverage, ceiling price formula (average of ≥1% share brands + 16% MAPE), WPI-linked annual revision, 10% cap for non-scheduled drugs.

NATIONAL PHARMACEUTICAL PRICING AUTHORITY (NPPA)

📌 **Definition:** The National Pharmaceutical Pricing Authority (NPPA) is an independent regulatory body established by the Government of India on 29th August 1997 to fix and revise prices of controlled bulk drugs and formulations, and enforce provisions of the DPCO. It functions under the Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals.

NPPA —Facts

Attribute	Details
Established	29th August 1997
Head Office	New Delhi
Parent Ministry	Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals
Chairperson	IAS Officer of Joint Secretary rank (Government of India)
Legal Authority	Derives powers from the Essential Commodities Act 1955 and DPCO 2013
Website	www.nppaindia.nic.in
Key Publication	NPPA official gazette notifications on ceiling prices

Functions & Powers of NPPA

- **Price Fixation:** Fixes ceiling prices for all Scheduled Formulations (NLEM drugs) based on the DPCO 2013 formula.
- **Price Revision:** Revises prices of scheduled drugs annually based on WPI movement; revises non-scheduled drug prices upon company request (within 10% cap).
- **Monitoring & Enforcement:** Monitors manufacturer compliance with notified ceiling prices; takes action against overpricing through inspection and audit.

- **Overpricing Recovery:** Directs companies to deposit excess amounts (overcharged above ceiling price) along with 15% annual interest to the government.
- **Granting Price Approvals:** Reviews and approves price revision requests for non-scheduled drugs beyond 10% cap (in exceptional cases).
- **Market Intelligence:** Collects and analyses retail market price data, company sales data, and market share information through periodic audits.
- **Public Information:** Publishes list of ceiling prices in public domain — enabling patients and pharmacists to check correct MRP.
- **Inter-Ministerial Coordination:** Works with CDSCO, Ministry of Health, and state drug controllers to ensure drug pricing compliance.
- **Advisory Role:** Advises the government on pricing policy, essential medicines list updates, and pharmaceutical market issues.

NPPA's Price Monitoring & Recovery System

- Field Officers: NPPA has Drug Price Control Enforcement Officers in each state who conduct surprise inspections of manufacturing premises and retail pharmacies.
- Overpricing Cases: If a brand is found selling above the ceiling price, NPPA issues a demand notice for recovery of overcharged amount + 15% interest.
- Public Grievance Cell: Patients and pharmacists can report overpriced drugs through the NPPA online portal.
- Annual Reports: NPPA publishes annual reports on overpricing cases detected, amounts recovered, and enforcement actions taken.
- Paragraph 20 Orders: NPPA can invoke emergency price control on any drug in public interest — even non-scheduled drugs — under Paragraph 20 of DPCO 2013.

Point: Under Paragraph 19 of DPCO 2013, the government can fix the price of ANY drug (scheduled or non-scheduled) in extraordinary circumstances to protect public health — even if not covered under routine DPCO provisions. This was invoked during COVID-19 for drugs like Remdesivir and Favipiravir.

DPCO vs. NPPA — Quick Comparison

Aspect	DPCO	NPPA
Nature	A statutory government ORDER (law)	A government AUTHORITY (regulatory body)
Purpose	Legal framework for drug price control in India	Body that implements and enforces the DPCO
Current Version	DPCO 2013 (replaces DPCO 1995)	Established 1997; functional since 1997
Authority Source	Essential Commodities Act, 1955	Powers derived from DPCO + Essential Commodities Act
Key Action	Defines which drugs are price-controlled and formula	Calculates, notifies and enforces ceiling prices
Analogy	Like a law / constitution for drug pricing	Like a court / police that enforces the law

PART B — EMERGING CONCEPTS IN PHARMACEUTICAL MARKETING

VERTICAL MARKETING SYSTEMS (VMS)

📌 **Definition:** A Vertical Marketing System (VMS) is a professionally managed and centrally coordinated distribution channel system designed to achieve channel economies and maximum market impact. In a VMS, channel members at different levels (manufacturer, wholesaler, retailer) work together as a unified system rather than independently.

Types of Vertical Marketing Systems

- **A. Corporate VMS:** A single company owns and operates multiple levels of the channel — manufacturer, distributor, and retailer are all under one corporate entity. Example: A pharma company that owns its own C&F depots, wholesale distribution network, and retail pharmacy chains — e.g., Apollo Pharmacy group owning the entire chain from distribution to retail.
- **B. Contractual VMS:** Independent firms at different channel levels integrate through formal contracts — sharing coordination without common ownership.

  - Franchise System: Pharma retailer franchise networks — e.g., MedPlus franchise, Apollo Pharmacy franchise, Wellness Forever franchise — franchisee operates under franchisor's brand, systems, and supply chain.
  - Retailer Co-operatives: Groups of retail pharmacists forming a cooperative to buy directly from manufacturers, gaining better margins.
  - Wholesaler-Sponsored Voluntary Chains: Stockist/distributor sponsoring a group of retailers under a unified marketing program.
- **C. Administered VMS:** Coordination achieved not through ownership or contracts but through the sheer size and power of one channel member who influences others' behaviour. Example: A dominant pharma company like Sun Pharma or Cipla dictating shelf space, pricing, and promotional activities to stockists and retailers through their market dominance.

Advantages of VMS in Pharmaceutical Distribution

Advantage	Pharma Application
Better coordination & control	Consistent product storage, handling, and dispensing across all channel members
Economies of scale	Bulk purchasing, centralised logistics, shared marketing costs
Reduced channel conflict	Unified objectives across members reduce inter-channel disputes
Better consumer experience	Standard pharmacy experience — same quality, same service, same pricing
Data integration	Integrated sales data from all channel levels for better demand forecasting

HORIZONTAL MARKETING SYSTEMS (HMS)

📌 **Definition:** A Horizontal Marketing System (HMS) is an arrangement where two or more companies at the same channel level combine resources (capital, production capacity, marketing) to exploit a marketing opportunity that neither could pursue alone. Also called symbiotic marketing or strategic alliance.

Types of Horizontal Marketing Arrangements

- **Strategic Alliance:** Two pharma companies collaborate on R&D, clinical trials, or market co-promotion — sharing costs and risks.

- **Co-Promotion Agreement:** Two companies jointly promote the same product — one provides the molecule, the other provides the sales force/distribution network. Example: Company A (with strong NCE but weak field force) partners with Company B (strong MR network) to co-promote the product.
- **Licensing Agreement:** Company A licenses its patented drug to Company B for manufacture and sale in a specific territory — both benefit. Example: Roche licensing its cancer drug to a generic company in India for local manufacture.
- **Co-Manufacturing:** Two companies share manufacturing capacity — one produces the API, another does formulation and finishing.
- **Retail Alliance:** Multiple pharmacy chains forming a joint purchasing or marketing alliance for better margins.

Pharma Horizontal Marketing Examples

Example	Companies Involved	Nature of Alliance
COVID-19 Vaccine	AstraZeneca + Serum Institute of India	Manufacturing and distribution alliance for Covishield vaccine in India
HIV Treatment	UNAIDS + Generic Indian Pharma (Cipla)	Horizontal alliance providing affordable ARVs globally at reduced prices
Co-Promotion India	MNC Pharma + Indian Pharma Company	MNC provides molecule; Indian company provides pan-India MR network
Pharmacy Chains	MedPlus + Apollo Pharmacy (market level)	Both operate as horizontal competitors but may share drug procurement portals
Research Partnership	Sun Pharma + CSIR (Council of Scientific & Industrial Research)	R&D collaboration on new molecule development

Point: Horizontal Marketing is becoming increasingly common in pharma — smaller companies form alliances to compete with MNC giants. India's pharmaceutical export success is partly built on horizontal collaboration between generic manufacturers and global health agencies (WHO, MSF).

RURAL PHARMACEUTICAL MARKETING

Definition: Rural pharmaceutical marketing refers to the strategies, approaches, and challenges involved in making pharmaceutical products and

healthcare services available, affordable, and accessible to the rural population of India. With 65% of India's 1.4 billion population living in rural areas, rural pharma marketing represents a massive, largely untapped market opportunity.

Size & Importance of the Rural Pharma Market

- India has 6.4 lakh villages — reaching all of them requires a fundamentally different marketing approach from urban strategies.
- Rural India contributes ~20–25% of total Indian pharmaceutical market revenue but represents 65% of the population — indicating significant under-penetration.
- Government health schemes — Ayushman Bharat, PM-JAY, PMJAY, NRHM — are rapidly expanding rural healthcare access, creating new pharma market opportunities.
- Jan Aushadhi Scheme: Over 10,000 PM Bharatiya Janaushadhi Kendras (PMBJK) providing generic medicines at 50–90% cheaper than branded equivalents in rural/semi-urban areas.

Challenges in Rural Pharmaceutical Marketing

Challenge	Description	Impact
Distribution Infrastructure	Poor road connectivity, limited cold chain logistics, few trained channel partners in remote villages	Limited drug availability — patients travel long distances for medicines
Healthcare Access	Shortage of qualified doctors, pharmacists, and healthcare facilities in rural areas	Prescription generation is limited — OTC self-medication dominates rural market
Low Income & Affordability	Low per capita income in rural areas — price sensitivity is extreme	Generic and Jan Aushadhi products preferred; branded drugs unaffordable
Low Literacy	Product labelling and patient information often not understood	Incorrect drug use, non-compliance, self-medication errors
Communication Barriers	Regional language diversity; limited internet penetration in remote areas	Mass media advertising less effective; MR visits to rural areas costly

Challenge	Description	Impact
Quackery & Traditional Medicine	Widespread reliance on unqualified practitioners ('quacks') and traditional remedies in rural areas	Patients may prefer alternative remedies or quack prescriptions over modern medicines
Small Order Sizes	Retailers in villages order very small quantities — uneconomical for stockists to serve directly	Supply chain gaps; stockouts common in rural pharmacies

Strategies for Rural Pharmaceutical Marketing

- **4As Framework for Rural Marketing:** Availability, Affordability, Awareness, and Acceptability — the four pillars of successful rural pharma marketing.
- **Hub-and-Spoke Distribution:** Larger town (hub) stockist services surrounding villages (spokes) through periodic delivery vans or mobile distribution units.
- **Van-Based Rural Distribution:** Companies deploying mobile drug vans for periodic visits to rural villages — combining distribution with health camps.
- **Jan Aushadhi Centres (PMBJK):** Selling affordable generic medicines through government-approved retail outlets in rural areas.
- **Rural-Specific Pack Sizes:** Smaller, more affordable pack sizes — e.g., a 4-tablet mini-strip instead of 10-tablet strip for price-sensitive rural buyers.
- **ASHA Worker & ANM Partnerships:** Leveraging ASHA (Accredited Social Health Activist) workers and ANMs (Auxiliary Nurse Midwives) as health product distributors and demand generators for OTC/essential products.
- **Telemedicine Integration:** Connecting rural patients with urban doctors through telemedicine platforms — generating prescriptions that can be dispensed at nearest pharmacy.
- **e-Choupal / Kiosk Model:** Digital health kiosks in gram panchayat offices or rural community centres providing health information and drug dispensing.
- **Language & Cultural Adaptation:** Promotional materials, drug labels, and health education content in regional languages and culturally relevant formats.

Remember: India's rural pharma market is projected to grow at 10–12% CAGR (faster than urban 8–9%) as government health schemes, telemedicine, and digital payment penetration improve rural healthcare access.

CONSUMERISM IN PHARMACEUTICAL MARKETING

📌 **Definition:** Consumerism is a social movement that seeks to protect the rights and interests of consumers against unethical, deceptive, or harmful business practices. In pharmaceutical marketing, consumerism has significant implications as drugs are uniquely positioned at the intersection of commerce and healthcare — where commercial interests can conflict with patient welfare.

Consumer Rights in Healthcare (Philip Kotler)

- **Right to Safety:** Patients have the right to be protected from harmful drugs, medical devices, and treatments. Example: Strict drug approval process (CDSCO); post-market pharmacovigilance.
- **Right to Be Informed:** Patients have the right to complete, accurate information about drugs — ingredients, side effects, contraindications. Example: Mandatory package insert, patient information leaflet, label disclosures.
- **Right to Choose:** Patients have the right to choose between branded and generic drugs, between different healthcare providers. Example: CDSCO's Generic Medicine Prescription Policy.
- **Right to Be Heard:** Consumer grievances must be addressed by manufacturers and regulatory authorities. Example: ADR (Adverse Drug Reaction) reporting systems; consumer courts.
- **Right to Seek Redressal:** Patients have the right to legal recourse for harm caused by substandard or spurious drugs. Example: Consumer Protection Act 2019 — applicable to pharmaceutical products and services.
- **Right to Consumer Education:** Patients have the right to be educated about diseases, drugs, and rational health choices. Example: CDSCO drug literacy campaigns; pharmacist counselling mandate.

Consumerism Issues in Pharma Marketing

- Irrational Fixed-Dose Combinations (FDCs): Banning of 344 irrational FDCs by CDSCO in 2016 — protecting consumers from unnecessary, potentially harmful drug combinations.
- Misleading Drug Advertising: The Drug & Magic Remedies Act 1954 and ASCI code protect consumers from false claims — e.g., 'guaranteed cure for cancer' type advertising.

- Right to Generic Prescriptions: Medical Council of India (MCI/NMC) mandate that physicians prescribe in generic names — empowering patients to choose affordable alternatives.
- Spurious Drugs Menace: Counterfeit drugs affecting patient safety — consumerism movement demands stricter track-and-trace, QR codes, and serialisation.
- Data Privacy: Patient health data collected by e-pharmacies, health apps must be protected under consumerism principles and Personal Data Protection Bill.
- Drug Pricing Transparency: Consumer right to know MRP and not be overcharged — Jan Aushadhi price lists, NPPA ceiling price public database.

Pharmaceutical Consumerism — Regulatory Response

- Consumer Protection Act 2019: Covers pharmaceutical products; patients can file complaints for defective medicines, overcharging, and false advertising.
- UCPMP (Uniform Code for Pharmaceutical Marketing Practices): Protects physicians and patients from unethical pharmaceutical marketing practices.
- Pharmacovigilance Programme of India (PvPI): CDSCO's national program for reporting and monitoring adverse drug reactions — direct consumer safety tool.
- Indian Medical Registry & Telemedicine Guidelines: Regulate online healthcare services in the interest of consumer protection.

INDUSTRIAL (B2B) PHARMACEUTICAL MARKETING

📌 **Definition:** Industrial pharmaceutical marketing (also called B2B or institutional pharma marketing) refers to marketing of pharmaceutical products, APIs (Active Pharmaceutical Ingredients), drug delivery systems, and pharmaceutical services to businesses, institutions, and organisations rather than individual consumers. The buyers are hospitals, nursing homes, government health departments, bulk manufacturers, research institutions, and pharmaceutical companies themselves.

Types of Industrial Pharmaceutical Markets

Industrial Market Segment	Buyers	Products Marketed
Hospital & Institutional Market	Government hospitals, private hospitals, nursing homes, medical colleges	Injectable drugs, OT supplies, ICU medications, surgical antimicrobials, IV fluids

Industrial Market Segment	Buyers	Products Marketed
API / Bulk Drug Market	Pharmaceutical formulation manufacturers	Active Pharmaceutical Ingredients (APIs), intermediates, excipients
Government Procurement Market	Central government, state health departments, armed forces, railways	Essential medicines, vaccines, family planning products at tender prices
Research & Academic Market	Medical colleges, research institutions, CSIR labs, ICMR	Reference standards, analytical reagents, clinical trial drugs
Veterinary Market	Animal farms, veterinary hospitals, pet care centres	Veterinary antibiotics, dewormers, growth promoters, vaccines for animals
Export Market (B2B)	Foreign pharma companies, global health agencies (WHO, UNICEF, MSF)	Finished dosage forms, APIs, biosimilars — especially to regulated markets

Characteristics of Industrial Pharma Marketing (B2B vs. B2C)

Aspect	Industrial / B2B Marketing	Consumer / B2C Marketing
Buyer Type	Hospitals, government, manufacturers — professional organisations	Patients, caregivers — individual consumers
Purchase Decision	Committee-based — formulary committee, purchase dept, physician head	Individual or family-based decision
Purchase Volume	Large bulk quantities — thousands of units per order	Small quantities — one strip, one bottle
Price Determination	Negotiated, tender-based, contract pricing	Fixed MRP printed on pack
Buying Motivation	Rational — efficacy, safety, cost, regulatory compliance	Emotional + rational — brand trust, doctor advice
Relationship Importance	Long-term contractual relationships critical	Transactional — less relationship-dependent

Aspect	Industrial / B2B Marketing	Consumer / B2C Marketing
Promotional Tools	Key Account Management, hospital detailing, formulary listing, tenders	MR detailing, advertising, OTC promotions
Geographic Concentration	Fewer buyers but geographically concentrated in hospital hubs	Millions of buyers dispersed across geographies

Hospital Formulary —Industrial Marketing Concept

- A hospital formulary is an approved list of drugs selected for use within a hospital, based on evidence-based criteria — efficacy, safety, cost-effectiveness.
- Getting a drug listed on the hospital formulary is the critical objective of industrial pharma marketing to hospitals.
- Formulary Committee: Consists of senior physicians, pharmacists, hospital administrator, and infection control specialist.
- Formulary listing strategy: Companies provide clinical evidence dossiers, pharmaeconomic data, and engage KOLs within the hospital to support listing.
- Once listed — product is purchased and used by all relevant departments in the hospital.

GLOBAL PHARMACEUTICAL MARKETING

📌 **Definition:** Global pharmaceutical marketing refers to the development and execution of marketing strategies that address international markets, recognising that diseases, patient needs, healthcare systems, and regulatory environments vary significantly across countries. India is the world's pharmacy — supplying ~60% of global vaccine requirements and ~50% of Africa's generic medicines demand.

India's Position in Global Pharmaceutical Trade

Metric	India's Global Standing
Generic Drug Supply	Largest supplier globally — provides ~20% of global generic medicine requirements by volume
Vaccine Supply	Supplies ~60% of vaccines for global immunisation programs (WHO, UNICEF, GAVI)

Metric	India's Global Standing
Pharma Export Value	USD 25+ billion annual exports (2023–24)
Export Markets	200+ countries; USA (largest, ~30%), Europe, Africa, Southeast Asia, Australia
USFDA-Approved Plants	India has most USFDA-approved manufacturing plants outside USA (~600+ approved sites)
Generic Market Leadership	Cipla's Triomune (AIDS drug) transformed global HIV treatment at USD 1/day — seminal global marketing achievement

Standardisation vs. Adaptation in Global Pharma Marketing

Element	Standardised (Same Globally)	Adapted (Changed by Country)
Product (Active Ingredient)	Same API molecule and formulation	Dosage form may differ — e.g., sachets in Africa, tablets in USA
Brand Name	Global brand names standardised (Augmentin, Lipitor)	Sometimes different names in different markets due to trademark issues
Packaging	Similar secondary packaging design	Label language, mandatory warnings differ by country regulation
Pricing	Very different globally — USA highest; India among lowest	Tiered pricing by country income level (Differential pricing)
Regulatory Dossier	Core clinical data package same globally	Regulatory filing format different — ICH CTD for USA/EU vs. national formats
Promotion	Scientific rationale same worldwide	Promotional tools differ — TV for USA OTC; MR for India Rx; digital for EU

Global Pharmaceutical Marketing Strategies

- **Regulated Market Strategy (USA, EU, Japan):** Companies obtain USFDA/EMA approvals for high-value generic drugs — complex, expensive but commands premium pricing and high volume. Key players: Sun Pharma, Dr. Reddy's, Lupin, Cipla — all have strong ANDA (Abbreviated New Drug Application) portfolios.

- **Semi-Regulated Market Strategy (Africa, Southeast Asia, Latin America):** Easier regulatory approvals; high volume generic drug supply at competitive prices. Key strategy for pan-India manufacturers reaching emerging markets.
- **Contract Manufacturing / CDMO:** Indian companies manufacturing for global innovators on contract — leveraging low-cost, high-quality manufacturing advantage. Examples: Jubilant, Divi's Laboratories, Piramal Pharma.
- **Biosimilar Market Entry:** Developing biosimilar versions of blockbuster biologics (insulin, monoclonal antibodies) for regulated global markets — high value strategy. Examples: Biocon's insulin biosimilars in USA and Europe.
- **Brand Building in Export Markets:** Cipla's 'Caring for Life' global brand, Dr. Reddy's 'Good Health Can't Wait' — building global brand equity beyond generic commoditisation.

Regulatory Requirements for Global Pharmaceutical Marketing

Region	Regulatory Authority	Key Requirement for Market Entry
United States	USFDA (US Food and Drug Administration)	NDA (New Drug Application) or ANDA (generic); cGMP compliance; plant inspection
European Union	EMA (European Medicines Agency)	Marketing Authorisation (MA) via centralised or mutual recognition procedure
Japan	PMDA (Pharmaceuticals & Medical Devices Agency)	JNDA approval; Japanese clinical trial data often required
India	CDSCO (Central Drugs Standard Control Organisation)	Form 44 import licence or local manufacturing approval
WHO Prequalification	WHO — for UN/UNICEF/GAVI procurement	WHO GMP and quality standards — essential for global health procurement
Africa (Stringent)	SAHPRA (South Africa)	Registration through SAHPRA or AU-REC (African Union regulatory process)

Global Note: India's pharmaceutical global marketing success is built on three pillars: (1) Low-cost manufacturing with high-quality GMP standards, (2) Large pool of English-speaking scientific talent, and (3) Robust domestic market experience that builds expertise before global expansion.

★ **Exam Tip:** Highest-Frequency Topics across all units: (1) DPCO & NPPA — always 5–10 marks. (2) Product Life Cycle — always appears. (3) BCG Matrix — always appears. (4) PSR duties, training, compensation. (5) Online promotional techniques for OTC. (6) Channel conflict and resolution. (7) Market Research — IQVIA. Always link theory to pharmaceutical examples for full marks.

— Best Of Luck For Your Exam —

BP803ET Pharma Marketing Management — All 5 Units Complete

www.noteskarts.com | B.Pharm 8th Semester | As per PCI/AKTU Syllabus